T-cell engagement with a difference
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
EHA 2024 – In8bio bets on a registrational plan
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
ASH 2023 movers – an unexpected comeback for MorphoSys
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
